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Diagnostic and prognostic values of antikeratin antibodies (AKA)  
and collagen III propeptides (PIIINP) in juvenile rheumatoid arthritis. 
 
INTRODUCTION 
JRA is one of the most common rheumatic diseases of 
children. It is characterized by an idiopathic synovitis 
of the joints, associated with soft tissue swelling and 
effusion 1. 
Advances in exploring joint tissue composition and 
pathophysiology have defined a number of biological 
markers that can serve as good diagnostic and 
prognostic predictors 2. Antikeratin antibodies (AKA) 
are detectable at the time of initial diagnosis of adult 
RA and its positivity may have prognostic significance 
in the disease course 3,4. Furthermore, it is considered 
now as one of the specific serological markers of RA 5. 
PIIINP is a marker of type III collagen synthesis as 
well as an indicator of inflammation and healing 
processes in the joints 6. PIIINP was reported to reflect 
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disease activity and to correlate with the grade of joint 
destruction in adult RA 7.  
This study is aimed at evaluation of AKA and PIIIPN 
as diagnostic and prognostic markers in JRA. 
 
METHODS 
The study comprised 31 patients who fulfilled the 
American Association Criteria Update for Diagnosis of 
JRA 1,8. They were enrolled from the Pediatric Allergy 
and Immunology Unit, Ain Shams University. They 
were 15 males and 16 females. Their age ranged from 
4 to 17 years with a mean age of 10.6±4.2 years and a 
mean duration of illness of 53.7±42.4 months. Out of 
the 31 patients, eleven had knee effusion. 
Any patient with evidence of hepatic or renal 
affection was excluded from the study to avoid extra-
articular sources of changed PIIINP metabolism. 
The patients were subgrouped into: 
Group I : Comprised 20 patients with poly-
articular JRA. 
Group II : Comprised 5 children with pauci-
articular JRA. 
Group III :Comprised 6 children with systemic onset 
JRA. 
The patients were compared to two control groups 
consisting of 25 age and sex matched children. The 
first group comprised 15 healthy children  with a mean 
age of 9.8±4.7 years and the second comprised 10 
systemic lupus erythematosus patients who were 
having arthritis with a mean age of 11.4±5.1 years. 
All patients were subjected to : 
I. Clinical history taking : to verify the diagnosis, 
duration of   illness and the disease course. 
II. Joints clinical evaluation : three clinical indices 
were used : 
A. Joint swelling: graded from 0 to 3. 
B. Pain or joint tenderness : graded from 0 to 3. 
C. Limitation of movement (LOM): graded from 0 to 
4. 
Activity score was calculated according to 
Giannini et al., 1992 and VanRossum et al., 1998 9,10. 
Activity score = 
Sum of the 3 clinical indices for the examined joints 
                    Number of the affected joints  
III. Laboratory investigations : 
1. Routine investigations : 
- ESR (Westergren method). 
- C-reactive protein (latex agglutination test kit, Biotec 
Laboratories Ltd, UK).   
- Complete blood picture (Coulter MicroDiff 18,USA). 
- Serum rheumatoid factor (RF) by latex agglutination 
(Avitex-RF;Omega Diagnostics,UK). 
- Antinuclear antibodies by indirect immuno-
fluorescent microscopy (Sanofi Diagnostics-
Pasteur,USA). 
2. Measurement of PIIINP in serum and synovial 
fluid (PIIINP radioimmunoassay diagnostic kit, Orion 
Diagnostica, Finland) 6. 
3. Detection of AKA in serum and synovial fluid 
(AKA immunofluorescence diagnostic kit, IMMCO 
Diagnostics, USA) 11. 
Sampling for CBC, ESR, PIIINP and AKA were 
repeated for  all patients after 3 months of the study 
onset. 
IV. Radiological Assessment : 
Knee joints, hands and feet were examined on 3 
occasions : at the study onset, after 3 months and after 
12 months. 
Radiograph assessment was carried out by : 
1. Rau and Herborn12 method (Modified Larsen 
Scoring Method): scoring soft tissue swelling, joint 
space-narrowing, erosions. 
2. Fuchs et al 13 method for scoring malalignment.  
Statistical Methods 
Statistical analysis of the results was done using a 
standard computer program (Statview 40, Abacus 
Concepts, Inc, Berkeley, CA,USA) employing the 
student t test as well as Mann-Whitney test for non- 
parametric data. The correlation coefficient ( r ) test 
was used to inter-relate the numerical data . 
 
RESULTS 
Serum PIIINP showed significant elevation at the 
study onset in JRA patients (12.8±8.7 μg/L) as 
compared to the healthy controls (7.0±1.9 μg/L, 
p<0.05). Meanwhile, comparing JRA patients to SLE 
patients with arthritis (10.2±3.1 μg/L) revealed non 
significant difference (p>0.05). After 3 months of 
proper treatment, no significant difference was 
observed between JRA patients (10.5±8.8 μg/L) and 
healthy children (7.03±1.95 μg/L, p>0.05) (Fig. 1). 
On comparing serum PIIINP to SF PIIINP 
(56.4±6.6 μg/L); PIIINP was significantly higher in 
synovial fluid.  
Serum AKA positivity was significantly higher in 
JRA patients at the study onset (77%) as compared to 
both healthy controls (7%, p<0.001) and SLE patients 
(10%, p<0.001). Three months later while still under 
treatment, serum AKA was significantly higher in JRA 
patients (90%) in comparison to both groups 
(p<0.001). Serum AKA showed increasing positivity 
with time despite treatment from 77% to 90%  (Fig. 2). 
Studying serum AKA sensitivity, specificity and 
diagnostic efficiency in JRA revealed percentage 
values of 77%, 93% and 83% respectively at the study 
onset, that increased to 90%, 93%, 91% respectively 
after 3 months  (Table 1). 























JRA patients SLE control Healthy control
 
JRA = Juvenile rheumatoid arthritis; SLE = Systemic lupus 
erythematosus; S. PIIINP = Serum aminoterminal propeptide of 
type III procollagen 
 
Fig. (1): Comparison of mean S. PNIIIP in all 
studied patients versus the control groups at study 


























JRA patients SLE control Healthy control
 
S. AKA = Serum antikeratin antibodies; JRA = Juvenile 
rheumatoid arthritis; SLE = Systemic lupus erythematosus 
 
Fig. (2): Comparison of mean S. AKA positivity in 
all studied patients versus the control groups at 
study onset and 3 months later. 
 
Synovial fluid AKA levels showed no significant 
difference as compared to those of serum AKA. The 3 
subgroups of JRA were statistically comparable to 
each other in terms of serum PIIINP and serum AKA. 
Also, groups on different modalities of treatment were 
quite  comparable to each other in serum PIIINP and 
AKA concentrations. 
Serum PIIINP and SF/S PIIINP had no significant 
correlation with other studied laboratory indices 
including serum AKA, total clinical activity score or 
radiological score. The only exception was that serum 
PIIINP correlated positively to one clinical index 
which is the limitation of movement LOM (r = 0.36, 
P<0.05)  (Fig.3). 
 
 
Table (1): S. AKA sensitivity, specificity and 
diagnostic efficiency for JRA at study onset and 3 
months later. 




S. AKA diagnostic 
efficiency 
Month 0 77% 93% 83% 
Month 3 90% 93% 91% 




Although the clinical activity score and laboratory 
indices showed significant improvement after 3 months 
of treatment (p>0.05) (Table 2), the radiological score 
did not show any significant change over 3 months or 
after 12 months (p>0.05). Moreover, 8 patients were 
reported to have some radiological changes after 12 
months. On comparing their serum PIIINP levels to 
those who had no radiological changes, no statistically 
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r = 0.36; p<0.05 (Sig) 
Fig. (3):Positive correlation between serum 
aminoterminal propeptide of type III procollagen 
(S. PIIINP) and limitation of movement (LOM). 
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Table (2): Comparison of the clinical scores of JRA 













n 30 30 30 28 
Month 0     
Mean 1.50 1.31 0.82 8.34 
± SD ± 0.37 ± 0.44 ± 0.40 ± 1.78 
Month 3     
Mean 1.09 0.88 0.59 5.28 
± SD ± 0.29 ± 0.32 ± 0.23 ± 2.18 










Table (3): Comparison of the mean S. PIIINP in 
patients with radiographic changes versus those 












Month 0     
n 8 23   
Mean 9.71 13.03 0.81 >0.05 
± SD ± 5.31 ± 9.54   
Month 12     
n 7 22   
Mean 14.50 9.17 0.05 >0.05 
± SD ± 16.6 ± 4.07   
S. PIIINP = Serum aminoterminal propeptide of type III 
procollagen; JRA = Juvenile rheumatoid arthritis 
 
DISCUSSION 
JRA is characterized by the presence of numerous 
serum antibodies to various antigens 14. However, most 
of these antibodies are poorly specific for JRA 15. 
Rheumatoid factor is present in approximately 8% only 
of total JRA cases 1. Moreover, the role of non specific 
markers of inflammation like ESR and CRP is limited 
in monitoring the disease course. Identification of 
reliable diagnostic and prognostic markers of the 
disease seems important16. 
In the current study two markers were investigated 
as potential diagnostic and prognostic markers in JRA 
namely collagen III propeptides (PIIINP) and 
antikeratin antibodies AKA. 
In agreement with Hakala et al. 7 who reported 
significant elevation of serum PIIINP in adult RA, we 
found it significantly elevated in the studied JRA 
children. PIIINP is one of the main fibrillar collagens 
present in the synovium, and is primarily synthesized 
during inflammation and proliferation 17. Therefore, it 
is expected that joint synovial tissue will be the main 
source of serum PIIINP in JRA patients. In the current 
study, a highly significant elevation was reported in 
synovial fluid taken from knee effusion in comparison 
to serum PIIINP level of the same patients. However, 
we could not record any superiority for SF/S PIIINP 
ratio over serum PIIINP in detecting disease activity, 
which may indicate that elevation of serum PIIINP 
might reflect its elevation in the synovial fluid. 
In a trial to study the specificity of serum PIIINP 
to JRA disease activity, its mean level was compared 
to that of a group of SLE patients with arthritis. No 
significant difference could be detected indicating that 
it might be a product of the joint inflammatory process 
rather than a specific marker for JRA. 
 Follow up after 3 months of proper treatment 
revealed significant drop in the clinical activity score 
and other laboratory parameters. Meanwhile, serum 
PIIINP showed significant drop to near normal level. 
This indicates that serum PIIINP could be used to 
monitor the therapeutic response in JRA . There was 
no significant correlation between the total clinical 
activity score and serum PIIINP; however, serum 
PIIINP correlated positively with LOM, which is one 
component of the complicated clinical activity score. 
LOM index in JRA patients usually reflects disease 
inflammatory activity rather than joint destruction 
explaining why PIIINP correlated only with this 
component of the clinical activity score. 
In the present study, there was no correlation 
between serum PIIINP and the radiological score. Also 
there was no significant difference in serum PIIINP 
between 8 cases who showed some radiological 
changes after 1 year and those who did not. The last 2 
results indicated that a prognostic value for serum 
PIIINP in JRA patients could not be elicited in this 
study. 
The prevalence of AKA positivity in the patients’ 
sera was (77%) at study onset, which was relatively 
higher when compared to other studies.  Gabay et al. 18 
reported 27% AKA seropositivity in their study on 
JRA, while Hromadnikova et al.19 reported 50% 
seropositivity. Paimela et al. 20 reported 40% positivity 
rate in adult RA patients. Ethnic variability and 
variations in disease duration might explain the 
difference. 
Abdel Baky et al. 
44 
A highly significant positivity of serum AKA was 
recorded in JRA patients (77%) in comparison to the 
healthy control group (7%) and also to SLE patients 
(10%) implying reasonable sensitivity and specificity 
of the test in JRA. The calculated AKA sensitivity, 
specificity and diagnostic efficiency in JRA patients at 
the study onset was 77%, 93% and 83% respectively. 
Meyer et al.4 reported 63% sensitivity and 93% 
specificity for AKA in their study on adult RA 
patients, results that seemed comparable to ours. 
AKA is considered one of the antifilaggrin 
autoantibodies (AFA). Filaggrin is thought to cross 
react with antibodies to a protein expressed by 
synoviocytes21. This may explain the diagnostic value 
of this marker. Another member of the (AFA) is the 
antiperinuclear factor (APF). El-Gamal et al.22 reported 
APF specificity, sensitivity and diagnostic efficiency in 
JRA of 92%, 53% and 74% respectively. The lower 
sensitivity of APF reported in their study, in 
comparison to AKA in our study, could be because of 
the technical difficulties in the procedure of APF 
estimation. 
After 3 months follow up, AKA seropositivity was 
significantly elevated from 77% to 90%. The 
calculated sensitivity, specificity and diagnostic 
efficiency increased to 90%, 93%, and 91% 
respectively. This means that diagnostic efficiency can 
improve with the advance in disease duration. In   
agreement, Paimela et al.20 reported elevation in the 
seropositivity of AKA in adult RA patients from 26% 
to 40% over 2 years. 
Serum or SF AKA had no correlation with clinical 
activity score, radiological score or other laboratory 
parameters. Gabay et al.18 came to the same conclusion 
that there was no relation between AKA and disease 
severity or activity in JRA patients. On the contrary, 
strong relation to disease activity and severity in adult 
RA was reported by Girbal and associates5. 
In conclusion, serum PIIINP may reflect the 
inflammatory process of the joints and is a good 
marker for therapeutic control. Serum AKA positivity 
seems to be a good diagnostic marker for JRA; 
however, the study could not prove any prognostic 
value for either of the two markers. 
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